Exelixis Stock Forecast for 2023 - 2025 - 2030
Updated on 04/18/2024
Exelixis Stock Forecast and Price Target
Exelixis's stock is projected to advance by 18.06% from the previous closing price if it reaches the average target of $27.00 by the year's end, as five reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $32.35 and a low-end estimate of $18.00. If you are interested in EXEL stock, it is important to also consider its competitors.
18.06% Upside
Exelixis Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Exelixis's Price has fallen from $13.08 to $0.00 – a 100.00% decrease. For next year, analysts predict Fair Value of $22.52, which would mean an increase of 100.00%. Over the next seven years, experts predict that Exelixis's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.37 | Buy/Sell | $130.51 | 10.87% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF220.10 | Buy/Sell | CHF307.83 | 23.81% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.42 | Buy/Sell | $32.87 | 19.98% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$47.84 | Buy/Sell | $58.15 | 14.97% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$901.19 | Buy/Sell | $961.26 | 16.51% |
Exelixis Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Exelixis's Revenue has grown by 85.33%, rising from $987.54M to $1.83B. For next year, analysts predict Revenue of $2.09B, which would mean an increase of 14.46%. Over the next seven years, experts predict that Exelixis's Revenue will grow at a rate of 39.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.25€ | Buy/Sell | 45.15€ | 21.90% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.72 | Buy/Sell | $77.05 | 46.43% |
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥5.90k | Buy/Sell | ¥9.58k | 42.28% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$107.10 | Buy/Sell | $188.32 | 77.40% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$40.91 | Buy/Sell | $55.60 | 47.15% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$88.38 | Buy/Sell | $85.71 | 13.15% |
Exelixis EBITDA Forecast for 2023 - 2025 - 2030
Exelixis's EBITDA has grown In the last three years, rising from $121.90M to $196.60M – a growth of 61.28%. In the next year, analysts believe that EBITDA will reach $484.65M – an increase of 146.52%. For the next seven years, experts predict that Exelixis's EBITDA will grow at a rate of 511.60%.
Exelixis EBIT Forecast for 2023 - 2025 - 2030
Exelixis's EBIT has seen impressive growth In the last three years, rising from $112.76M to $170.89M – a growth of 51.55%. In the next year, analysts believe that EBIT will reach $490.25M – an increase of 186.88%. For the next seven years, the forecast is for EBIT to grow by 403.71%.
Exelixis EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Exelixis's EPS has fallen from $0.61 to $0.00 – a 100.00% decrease. For next year, analysts predict EPS of $1.05, which would mean an increase of 100.00%. Over the next seven years, experts predict that Exelixis's EPS will grow at a rate of 100.00%.
.jpg)